|
MechanismEGFR exon 20 inhibitors |
|
|
Active Indication- |
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Cambridge Biomedical, Inc.
0 Patents (Medical) associated with Cambridge Biomedical, Inc.
100 Deals associated with Cambridge Biomedical, Inc.
100 Translational Medicine associated with Cambridge Biomedical, Inc.